• Publications
  • Influence
Relationship between antithrombotic activities of fucans and their structure
A low molecular weight fucan fraction extracted from the brown seaweed Ascophyllum nodosum was previously shown to exhibit dose‐related venous antithrombotic activity with an ED80 of about 20 mg/kg,Expand
Venous antithrombotic and anticoagulant activities of a fucoïdan fraction.
Fucoïdan extracted from marine flora shows promise as an antithrombotic drug in rabbits and in a Wessler model of venous thrombosis. Expand
Antithrombotic and anticoagulant activities of a low molecular weight fucoidan by the subcutaneous route.
LMW fucoidan has potent antithrombotic activity and a potentially weaker haemorrhagic effect (i.e. a smaller effect on coagulation tests and a smaller prolongation of the bleeding time) than dalteparin. Expand
A new experimental model of venous thrombosis in rats involving partial stasis and slight endothelium alterations.
Venous thrombus formation is induced in rats using saline flushing in a venous bag created in the vena cava and subsequent stasis by stricture of the vein and transmission electron microscopy demonstrated that flushing induces discrete endothelial lesions with no evident desendothelialisation areas. Expand
Pharmacologic and biochemical profiles of new venous antithrombotic beta-D-xyloside derivatives: potential antiathero/thrombotic drugs.
In vivo experimentation demonstrated that after treatment by these molecules an important elevation in circulating GAG occurred, with LF 05-0030 presenting the greatest activity, being five times higher than control levels, and dermatan sulfate levels were significantly increased over control values, believed to support the antithrombotic activity observed. Expand
Experimental venous thrombosis induced by homologous serum in the rat.
The purpose of the present study was to compare the activities of heterologous and homologous serum as hypercoagulating agents in a rat stasis model of venous thrombosis using Wessler's technique. Expand
The venous antithrombotic effect of LF 1351 in the rat following oral administration.
LF 1351 demonstrated a dose-related antithrombotic effect in three models of venous thrombosis and was approximately equipotent in two models involving complete stasis of the vena cava and administration of factor Xa or porcine serum. Expand
5a-Carba-β-D-, 5a-Carba-β-L- and 5-Thio-β-L-xylopyranosides as New Orally Active Venous Antithrombotic Agents
Mitsunobu displacement of (-)-(1S,4R,5S,6S) -4,5,6-tris{[(tert-butyl)dimethylsilyl] oxy}cyclohex-2-en-1-ol ((-)-12; a (-)-conduritol-F derivative) with 4-ethyl-7-hydroxy-2H-1-benzopyran-2-one (16)Expand
The venous antithrombotic profile of naroparcil in the rabbit.
The venous antithrombotic profile of naroparcil or (4-[4-cyanobenzoyl]-phenyl)-1.5-dithio-beta-D-xylopyranoside was investigated in the rabbit following single i.v. and oral administration and thrombin generation by the intrinsic pathway was reduced in a dose-related manner. Expand
Carbaxylosides of 4-ethyl-2-oxo-2H-benzopyran-7-yl as non-hydrolyzable, orally active venous antithrombotic agents.
Enantiomer (-)-2 was obtained from a (+)-conduritol F derivative that was more active than (+)-2 in the Wessler's model. Expand